TCRR earnings
TCR2 Therapeutics Inc. (TCRR) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsCompelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma
- Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsCompelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada
- gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NE
- TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid TumorsCAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T. In order to participate in the conference call, please register at https://bit.ly/3BTJ9Z7. Participants can register via this link up to ten minutes prior to start time. The webcast and presentation will be made ava
- TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of platform into autoimmune diseases with TRuC Tregs - TCR2 to host a webcast on Wednesday, October 20 at 8:00a.m. ET CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.
- TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall response rate (ORR) 31% in patients infused with gavo-cel following lymphodepletion - Meaningful survival benefit at 11.2 months for patients with refractory mesothelioma - Recommended Phase 2 Dose (RP2D) being refined after identification of the Maximum Tolerated Dose (MTD) - TCR2 to host a conference call on Friday, September 17 at 9:00a.m. ET CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company wi
- TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid TumorsCAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio webcast on Friday, September 17, 2021 at 9:00am E.T. to discuss extended data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors. The dataset will be an extension of the oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 17 at 14:20 CEST (8:20am ET) (Presentation #959O) that is part of the official ESMO P